Ulipristal acetate: A novel pharmacological approach for the treatment of uterine fibroids

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 285-292

  Biglia, Nicoletta ^a   Carinelli, Silvestro ^b   Maiorana, Antonio ^c   D'Alonzo, Marta ^a   Monte, Giuseppe Lo ^d   Marci, Roberto ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Medical treatment of uterine fibroids; Myomas; Selective progesterone receptor modulator; Ulipristal acetate; Uterine fibroids

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; ULIPRISTAL; PREGNANE DERIVATIVE;

AMENORRHEA; BREAST TENDERNESS; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM; HEADACHE; HEALTH CARE NEED; HOT FLUSH; HUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UTERUS BLEEDING; UTERUS MYOMA; DRUG EFFECTS; FEMALE; LEIOMYOMA;

ENDOMETRIUM; FEMALE; HUMANS; LEIOMYOMA; NORPREGNADIENES;

EID: 84894789922     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S54565     Document Type: Review

References (34)

1. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571-588.
2. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-973.
3. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172(1 Pt 1):14-18.
4. Andersen J. Growth factors and cytokines in uterine leiomyomas. Semin Reprod Endocrinol. 1996;14:269-282.
5. Fields KR, Neinstein LS. Uterine myomas in adolescents: case reports and a review of the literature. J Pediatr Adolesc Gynecol. 1996;9(4):195-198.
6. Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.
7. Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids [review]. Cochrane Database Syst Rev. 2009;3:CD007692.
8. Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94(1):371-374.
9. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010;82(1):41-55.
10. Ikomi A, Pepra EF. Efficacy of the levonorgestrel intrauterine system in treating menorrhagia: actualities and ambiguities. J Fam Plann Reprod Health Care. 2002;28(2):99-100.
11. Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):307-331.
12. Stovall TG, Muneyyirci-Delale O, Summitt RL, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol. 1995;86(1):65-71.
13. Lethaby A, Vollenhoven B, Sowter MC. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids [review]. Cochrane Database Syst Rev. 2001;2:CD000547.
14. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, Makedos GA, Vlassis GD. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007;110(3):643-649.
15. Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93(1):192-198.
16. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand. 1985;64(4):307-309.
17. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000;65(10-11): 585-592.
18. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26(3): 423-438.
19. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293-307.
20. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21(4): 318-324.
21. Talaulikar VS, Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):135-140.
22. Donnez J, Tatarchuk TF, Bouchard P, et al; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409-420.
23. Donnez J, Tomaszewski J, Vázquez F, et al; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421-432.
24. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734-739.
25. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591-598.
26. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31(6):556-569.
27. Bläuer M, Heinonen PK, Rovio P, Ylikomi T. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model. Eur J Pharmacol. 2008;592(1-3):13-18.
28. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975;122(2):262-263.
29. Hendrickson MR, Longacre TA, Keempson RL. The uterine corpus. In: Sternberg SS, editor. Diagnostic Surgical Pathology. Philadelphia: Lippincott; 1999:2203-2204.
30. Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90(2):382-386.
31. Frederick J, Hardie M, Reid M, Fletcher H, Wynter S, Frederick C. Operative morbidity and reproductive outcome in secondary myomectomy: a prospective cohort study. Hum Reprod. 2002;17(11):2967-2971.
32. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1990;163(4 Pt 1):1114-1119.
33. Brosens IA. Variable response of uterine leiomyomas after GnRH agonist therapy. Fertil Steril. 1997;68(5):948-949.
34. Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report. Steril. 1984;42(4):644-646.